Portage Biotech (NASDAQ:PRTG – Get Free Report) and Wave Life Sciences (NASDAQ:WVE – Get Free Report) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.
Analyst Recommendations
This is a summary of current ratings and price targets for Portage Biotech and Wave Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Portage Biotech | 0 | 1 | 0 | 0 | 2.00 |
| Wave Life Sciences | 0 | 1 | 8 | 1 | 3.00 |
Wave Life Sciences has a consensus target price of $22.22, suggesting a potential upside of 59.87%. Given Wave Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Wave Life Sciences is more favorable than Portage Biotech.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Portage Biotech | N/A | N/A | -$75.34 million | ($41.65) | -0.19 |
| Wave Life Sciences | $53.61 million | 39.55 | -$57.51 million | ($1.11) | -12.52 |
Wave Life Sciences has higher revenue and earnings than Portage Biotech. Wave Life Sciences is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Portage Biotech and Wave Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Portage Biotech | N/A | -342.34% | -196.47% |
| Wave Life Sciences | -66.50% | -280.57% | -52.90% |
Institutional and Insider Ownership
13.4% of Portage Biotech shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 42.1% of Portage Biotech shares are held by company insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Portage Biotech has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500.
Summary
Wave Life Sciences beats Portage Biotech on 10 of the 14 factors compared between the two stocks.
About Portage Biotech
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials. The company is based in Tortola, British Virgin Islands.
About Wave Life Sciences
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
